Literature DB >> 27122587

Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.

Aitor Nogales1, Marta L DeDiego1,2, David J Topham1,2, Luis Martínez-Sobrido3.   

Abstract

UNLABELLED: Influenza viral infections represent a serious public health problem, with influenza virus causing a contagious respiratory disease which is most effectively prevented through vaccination. Segments 7 (M) and 8 (NS) of the influenza virus genome encode mRNA transcripts that are alternatively spliced to express two different viral proteins. This study describes the generation, using reverse genetics, of three different recombinant influenza A/Puerto Rico/8/1934 (PR8) H1N1 viruses containing M or NS viral segments individually or modified M or NS viral segments combined in which the overlapping open reading frames of matrix 1 (M1)/M2 for the modified M segment and the open reading frames of nonstructural protein 1 (NS1)/nuclear export protein (NEP) for the modified NS segment were split by using the porcine teschovirus 1 (PTV-1) 2A autoproteolytic cleavage site. Viruses with an M split segment were impaired in replication at nonpermissive high temperatures, whereas high viral titers could be obtained at permissive low temperatures (33°C). Furthermore, viruses containing the M split segment were highly attenuated in vivo, while they retained their immunogenicity and provided protection against a lethal challenge with wild-type PR8. These results indicate that influenza viruses can be effectively attenuated by the rearrangement of spliced segments and that such attenuated viruses represent an excellent option as safe, immunogenic, and protective live-attenuated vaccines. Moreover, this is the first time in which an influenza virus containing a restructured M segment has been described. Reorganization of the M segment to encode M1 and M2 from two separate, nonoverlapping, independent open reading frames represents a useful tool to independently study mutations in the M1 and M2 viral proteins without affecting the other viral M product. IMPORTANCE: Vaccination represents our best therapeutic option against influenza viral infections. However, the efficacy of current influenza vaccines is suboptimal, and novel approaches are necessary for the prevention of disease caused by this important human respiratory pathogen. In this work, we describe a novel approach to generate safer and more efficient live-attenuated influenza virus vaccines (LAIVs) based on recombinant viruses whose genomes encode nonoverlapping and independent M1/M2 (split M segment [Ms]) or both M1/M2 and NS1/NEP (Ms and split NS segment [NSs]) open reading frames. Viruses containing a modified M segment were highly attenuated in mice but were able to confer, upon a single intranasal immunization, complete protection against a lethal homologous challenge with wild-type virus. Notably, the protection efficacy conferred by our viruses with split M segments was better than that conferred by the current temperature-sensitive LAIV. Altogether, these results open a new avenue for the development of safer and more protective LAIVs on the basis of the reorganization of spliced viral RNA segments in the genome.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27122587      PMCID: PMC4936145          DOI: 10.1128/JVI.00410-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

Authors:  M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

Review 3.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Authors:  Michael T Osterholm; Nicholas S Kelley; Alfred Sommer; Edward A Belongia
Journal:  Lancet Infect Dis       Date:  2011-10-25       Impact factor: 25.071

4.  A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication.

Authors:  Shuai Cao; Xiaoling Liu; Maorong Yu; Jing Li; Xiaojuan Jia; Yuhai Bi; Lei Sun; George F Gao; Wenjun Liu
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Influenza virus m2 ion channel protein is necessary for filamentous virion formation.

Authors:  Jeremy S Rossman; Xianghong Jing; George P Leser; Victoria Balannik; Lawrence H Pinto; Robert A Lamb
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

6.  Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.

Authors:  Andrew Cox; Steven F Baker; Aitor Nogales; Luis Martínez-Sobrido; Stephen Dewhurst
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

7.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

Review 8.  Toward a universal influenza virus vaccine: prospects and challenges.

Authors:  Natalie Pica; Peter Palese
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

9.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.

Authors:  K S Li; Y Guan; J Wang; G J D Smith; K M Xu; L Duan; A P Rahardjo; P Puthavathana; C Buranathai; T D Nguyen; A T S Estoepangestie; A Chaisingh; P Auewarakul; H T Long; N T H Hanh; R J Webby; L L M Poon; H Chen; K F Shortridge; K Y Yuen; R G Webster; J S M Peiris
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

Review 10.  Emerging roles for the influenza A virus nuclear export protein (NEP).

Authors:  Duncan Paterson; Ervin Fodor
Journal:  PLoS Pathog       Date:  2012-12-06       Impact factor: 6.823

View more
  26 in total

1.  Functional Evolution of Influenza Virus NS1 Protein in Currently Circulating Human 2009 Pandemic H1N1 Viruses.

Authors:  Amelia M Clark; Aitor Nogales; Luis Martinez-Sobrido; David J Topham; Marta L DeDiego
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Tyr82 Amino Acid Mutation in PB1 Polymerase Induces an Influenza Virus Mutator Phenotype.

Authors:  Tadasuke Naito; Kazumasa Shirai; Kotaro Mori; Hidetaka Muratsu; Hiroshi Ushirogawa; Ryosuke L Ohniwa; Kousuke Hanada; Mineki Saito
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

3.  Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine.

Authors:  Aitor Nogales; Laura Rodriguez; Caroline Chauché; Kai Huang; Emma C Reilly; David J Topham; Pablo R Murcia; Colin R Parrish; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

4.  NS1 Protein Amino Acid Changes D189N and V194I Affect Interferon Responses, Thermosensitivity, and Virulence of Circulating H3N2 Human Influenza A Viruses.

Authors:  Aitor Nogales; Luis Martinez-Sobrido; David J Topham; Marta L DeDiego
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans.

Authors:  Aitor Nogales; Marta L DeDiego; Luis Martinez-Sobrido; Kevin Chiem; David J Topham
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

6.  Influenza A Virus Studies in a Mouse Model of Infection.

Authors:  Laura Rodriguez; Aitor Nogales; Luis Martínez-Sobrido
Journal:  J Vis Exp       Date:  2017-09-07       Impact factor: 1.355

7.  A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections.

Authors:  Aitor Nogales; Gines Ávila-Pérez; Javier Rangel-Moreno; Kevin Chiem; Marta L DeDiego; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

8.  Generation, Characterization, and Applications of Influenza A Reporter Viruses.

Authors:  Kevin Chiem; Aitor Nogales; Luis Martinez-Sobrido
Journal:  Methods Mol Biol       Date:  2022

9.  Avian Influenza NS1 Proteins Inhibit Human, but Not Duck, RIG-I Ubiquitination and Interferon Signaling.

Authors:  Danyel Evseev; Domingo Miranzo-Navarro; Ximena Fleming-Canepa; Robert G Webster; Katharine E Magor
Journal:  J Virol       Date:  2022-09-07       Impact factor: 6.549

10.  The K186E Amino Acid Substitution in the Canine Influenza Virus H3N8 NS1 Protein Restores Its Ability To Inhibit Host Gene Expression.

Authors:  Aitor Nogales; Caroline Chauché; Marta L DeDiego; David J Topham; Colin R Parrish; Pablo R Murcia; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.